Restricted accessResearch articleFirst published online 2025-8
Concurrent Alzheimer's disease pathologies in Lewy body diseases affect cognition and glucose metabolism in the posterior cingulate gyrus: A multimodal PET study
Lewy body disease (LBD) is a neurodegenerative disease characterized by Lewy bodies, and it clinically presents dementia with Lewy bodies (DLB) and Parkinson's disease (PD). Alzheimer's disease (AD) pathologies frequently coexist with LBD, complicating the clinical manifestation.
Objective
We evaluated the impact of AD pathologies, including amyloid-β and tau depositions, on cognitive dysfunction and glucose metabolism in LBD using multiple positron emission tomography scans.
Methods
Our study cohort consisted of 14 patients diagnosed with LBD, including five from the PD spectrum and nine from the DLB spectrum. In addition, 12 amyloid-negative cognitively healthy controls (HCs) and 13 amyloid-positive AD-spectrum patients were included. We subsequently explored the influence of amyloid and tau deposition on cognitive dysfunction and glucose metabolism among the LBD patients.
Results
In the LBD group, 44.4% of the DLB patients were amyloid-positive, and all PD patients were amyloid-negative. While tau accumulation was lower than in AD and similar to HCs at the group level, tau accumulation in the AD signature region was correlated with cognitive dysfunction. Among the changes in glucose metabolism, the cingulate island sign (CIS) index was elevated compared to AD. However, as cognitive impairment progressed, the CIS index decreased, reflecting reduced metabolism in the posterior cingulate gyrus, which was closely associated with tau accumulation in the same region.
Conclusions
Our findings indicate that AD pathologies, and particularly tau accumulation, significantly impact both cognitive dysfunction and glucose metabolism in LBD. This underscores the importance of addressing AD-related changes in the clinical management of LBD patients.
RietdijkCDPerez-PardoPGarssenJ, et al.Exploring Braak's hypothesis of Parkinson's disease. Front Neurol2017; 8: 37.
2.
JellingerKAKorczynAD. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?BMC Med2018; 16: 34.
3.
RobinsonJLLeeEBXieSX, et al.Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain2018; 141: 2181–2193.
4.
IrwinDJLeeVMTrojanowskiJQ. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci2013; 14: 626–636.
5.
Colom-CadenaMGrau-RiveraOPlanellasL, et al.Regional overlap of pathologies in Lewy body disorders. J Neuropathol Exp Neurol2017; 76: 216–224.
6.
FerreiraDPrzybelskiSALesnickTG, et al.β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology2020; 95: e3257–e3268.
7.
RuffmannCCalboliFCBraviI, et al.Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol2016; 42: 436–450.
8.
ComptaYParkkinenLO'SullivanSS, et al.Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?Brain2011; 134: 1493–1505.
9.
CoughlinDXieSXLiangM, et al.Cognitive and pathological influences of tau pathology in Lewy body disorders. Ann Neurol2019; 85: 259–271.
10.
JackCRJr.BennettDABlennowK, et al.NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
11.
ShimadaHShinotohHHiranoS, et al.β-amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord2013; 28: 169–175.
12.
KantarciKLoweVJBoeveBF, et al.AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol2017; 81: 58–67.
13.
WoykKSahlmannCOHansenN, et al.Brain (18) F-FDG-PET and an optimized cingulate island ratio to differentiate Lewy body dementia and Alzheimer's disease. J Neuroimaging2023; 33: 256–268.
14.
IizukaTIizukaRKameyamaM. Cingulate island sign temporally changes in dementia with Lewy bodies. Sci Rep2017; 7: 14745.
15.
Graff-RadfordJMurrayMELoweVJ, et al.Dementia with Lewy bodies: basis of cingulate island sign. Neurology2014; 83: 801–809.
16.
HughesAJDanielSEKilfordL, et al.Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry1992; 55: 181–184.
17.
McKeithIGDicksonDWLoweJ, et al.Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology2005; 65: 1863–1872.
18.
EmreMAarslandDBrownR, et al.Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord2007; 22: 1689–1707.
19.
PetersenRCSmithGEWaringSC, et al.Mild cognitive impairment: clinical characterization and outcome. Arch Neurol1999; 56: 303–308.
20.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology2017; 89: 88–100.
21.
McKhannGDrachmanDFolsteinM, et al.Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology1984; 34: 939–944.
22.
AshburnerJ. A fast diffeomorphic image registration algorithm. Neuroimage2007; 38: 95–113.
23.
Tzourio-MazoyerNLandeauBPapathanassiouD, et al.Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage2002; 15: 273–289.
24.
KlunkWEKoeppeRAPriceJC, et al.The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement2015; 11: 1–15.e11–14.
25.
JackCRJr.WisteHJWeigandSD, et al.Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement2017; 13: 205–216.
26.
FarrellMEJiangSSchultzAP, et al.Defining the lowest threshold for Amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology2021; 96: e619–e631.
27.
EdisonPRoweCCRinneJO, et al.Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry2008; 79: 1331–1338.
28.
GompertsSNRentzDMMoranE, et al.Imaging amyloid deposition in Lewy body diseases. Neurology2008; 71: 903–910.
29.
GompertsSNLocascioJJMarquieM, et al.Brain amyloid and cognition in Lewy body diseases. Mov Disord2012; 27: 965–973.
30.
YooHSJeonSCavedoE, et al.Association of β-Amyloid and basal forebrain with cortical thickness and cognition in Alzheimer and Lewy body disease spectra. Neurology2022; 98: e947–e957.
31.
MashimaKItoDKameyamaM, et al.Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson's disease without dementia. Eur Neurol2017; 77: 231–237.
32.
BarageSHSonawaneKD. Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides2015; 52: 1–18.
33.
HanPShiJ. A theoretical analysis of the synergy of amyloid and tau in Alzheimer's disease. J Alzheimers Dis2016; 52: 1461–1470.
34.
SkillbäckTFarahmandBYRosénC, et al.Cerebrospinal fluid tau and amyloid-β1–42 in patients with dementia. Brain2015; 138: 2716–2731.
35.
TsigelnyIFCrewsLDesplatsP, et al.Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One2008; 3: e3135.
36.
MasliahERockensteinEVeinbergsI, et al.Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A2001; 98: 12245–12250.
37.
MakEReidRIPrzybelskiSA, et al.Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies. NPJ Parkinsons Dis2024; 10: 76.
38.
ChinKSYassiNChurilovL, et al.Prevalence and clinical associations of tau in Lewy body dementias: a systematic review and meta-analysis. Parkinsonism Relat Disord2020; 80: 184–193.
39.
RaskinJCummingsJHardyJ, et al.Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res2015; 12: 712–722.
40.
KramerMLSchulz-SchaefferWJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci2007; 27: 1405–1410.
41.
PanLMengLHeM, et al.Tau in the pathophysiology of Parkinson's disease. J Mol Neurosci2021; 71: 2179–2191.
42.
GiassonBIFormanMSHiguchiM, et al.Initiation and synergistic fibrillization of tau and alpha-synuclein. Science2003; 300: 636–640.
43.
GompertsSNLocascioJJMakaretzSJ, et al.Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol2016; 73: 1334–1341.
44.
KogaSOnoMSaharaN, et al.Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology. Mov Disord2017; 32: 884–892.
45.
PattersonLFirbankMJCollobySJ, et al.Neuropathological changes in dementia with Lewy bodies and the cingulate island sign. J Neuropathol Exp Neurol2019; 78: 717–724.
46.
VillainNDesgrangesBViaderF, et al.Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci2008; 28: 6174–6181.
47.
KhadhraouiEMüllerSJHansenN, et al.Manual and automated analysis of atrophy patterns in dementia with Lewy bodies on MRI. BMC Neurol2022; 22: 114.
48.
HanyuHShimizuSTanakaY, et al.MR Features of the substantia innominata and therapeutic implications in dementias. Neurobiol Aging2007; 28: 548–554.
49.
WhitwellJLWeigandSDShiungMM, et al.Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain2007; 130: 708–719.
50.
HansenNMüllerSJKhadhraouiE, et al.Metric magnetic resonance imaging analysis reveals pronounced substantia-innominata atrophy in dementia with Lewy bodies with a psychiatric onset. Front Aging Neurosci2022; 14: 815813.
51.
MüllerSJKhadhraouiEHansenN, et al.Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinson's disease on MRI. BMC Neurol2023; 23: 114.
52.
CraryJFTrojanowskiJQSchneiderJA, et al.Primary Age-Related Tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol2014; 128: 755–766.
53.
JackCRJrAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
54.
SimuniTChahineLMPostonK, et al.A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol2024; 23: 178–190.
55.
OkuzumiAHatanoTMatsumotoG, et al.Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med2023; 29: 1448–1455.
56.
QuadaltiCPalmqvistSHallS, et al.Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med2023; 29: 1964–1970.
57.
PalmqvistSRossiMHallS, et al.Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat Med2023; 29: 1971–1978.
58.
EndoHOnoMTakadoY, et al.Imaging α-synuclein pathologies in animal models and patients with Parkinson's and related diseases. Neuron2024; 112: 2540–2557.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
